Generic Name

Methyprylon

---

Classification

FDA Approved Indications

• Short-term management of insomnia

Mechanism of Action

Methyprylon depresses the central nervous system, producing sedative and hypnotic effects, likely through the modulation of GABA-A receptor activity, enhancing GABA's inhibitory effects.

Dosage and Administration

Adult: Initial: 300-600 mg at bedtime. Adjust based on response and tolerance.

Pediatric: Not recommended due to safety concerns.

Geriatric: Lower initial dose recommended, e.g., 300 mg or less, to reduce risk of adverse effects.

Renal Impairment: Adjust dose based on severity; cautious use recommended.

Hepatic Impairment: Use with caution; no specific dosing guidelines available.

Pharmacokinetics

Absorption: Well absorbed orally.

Distribution: Widely distributed, crosses blood-brain barrier.

Metabolism: Metabolized in the liver.

Excretion: Excreted in urine, primarily as metabolites.

Half Life: Approximately 4-8 hours.

Contraindications

• Hypersensitivity to methyprylon or barbiturates.
• Obtain a complete medication history to avoid drug interactions.

Precautions

• Use with caution in elderly, debilitated patients, or those with compromised respiratory function, history of substance abuse, or hepatic impairment.

Adverse Reactions - Common

• Drowsiness, dizziness, headache. (Common.)
• Nausea, vomiting. (Less common.)

Adverse Reactions - Serious

• Respiratory depression, dependence, withdrawal symptoms. (Serious but less common.)
• Anaphylaxis or allergic reactions. (Rare.)

Drug-Drug Interactions

• Other CNS depressants, including alcohol, benzodiazepines, and opioids, which can increase sedation and respiratory depression.

Drug-Food Interactions

N/A

Drug-Herb Interactions

N/A

Nursing Implications

Patient/Family Teaching

• Take medication exactly as prescribed.
• Do not operate machinery or drive until effects are known.
• Avoid alcohol and other CNS depressants.
• Report signs of allergic reactions or excessive sedation.

Special Considerations

Black Box Warnings:

• Respiratory depression, addiction, withdrawal risks associated with barbiturates.

Genetic Factors: N/A

Lab Test Interference: N/A

Overdose Management

Signs/Symptoms: Excessive sedation, respiratory depression, coma, hypotension.

Treatment: Supportive care, airway management, activated charcoal if early, and possibly hemodialysis in severe cases.

Storage and Handling

Storage: Store at room temperature away from moisture, heat, and light.

Stability: Stable under recommended conditions.